ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för osimertinib mesylate. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

18 träffar

Bibliografisk träff 2021-11-01

A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.

Wu YL, Tsuboi M, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS.

Future Oncol · comment; patient education handout · DOI 10.2217/fon-2021-0752

Bibliografisk träff 2021-09-01

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.

Lamb YN.

Target Oncol · review-article; review; journal article · DOI 10.1007/s11523-021-00839-w

Bibliografisk träff 2021-06-22

Investigation of the mechanical effects of targeted drugs on cancerous cells based on atomic force microscopy.

Zhu J, Tian Y, Wang Z, Wang Y, Zhang W, Qu K, Weng Z, Liu X.

Anal Methods · research support, non-u.s. gov't; journal article · DOI 10.1039/d1ay00649e

Bibliografisk träff 2021-04-01

New Adjuvant Drug for Lung Cancer.

Aschenbrenner DS.

Am J Nurs · journal article · DOI 10.1097/01.naj.0000742492.40886.52

Bibliografisk träff 2020-03-02

Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease: A Systematic Review and Meta-analysis.

Erickson AW, Brastianos PK, Das S.

JAMA Netw Open · meta-analysis; research support, non-u.s. gov't; research-article; systematic review; journal article · DOI 10.1001/jamanetworkopen.2020.1617

Bibliografisk träff 2018-11-01

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA.

JAMA Oncol · research-article; journal article · DOI 10.1001/jamaoncol.2018.2969

Bibliografisk träff 2018-06-01

Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer.

Alsharedi M, Bukamur H, Elhamdani A.

Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2018.54.6.2817668

Bibliografisk träff 2017-09-29

Osimertinib - effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors.

Skrzypski M, Szymanowska-Narloch A, Dziadziuszko R.

Contemp Oncol (Pozn) · journal article; case reports; case-report · DOI 10.5114/wo.2017.70116

Bibliografisk träff 2017-08-01

Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer.

Lamb YN, Scott LJ.

Target Oncol · review; journal article · DOI 10.1007/s11523-017-0519-0

Bibliografisk träff 2016-12-06

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer.

Khozin S, Weinstock C, Blumenthal GM, Cheng J, He K, Zhuang L, Zhao H, Charlab R, Fan I, Keegan P, Pazdur R.

Clin Cancer Res · multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-16-1773

Bibliografisk träff 2016-12-01

AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC.

Papadimitrakopoulou VA.

Lung Cancer Manag · discussion; journal article · DOI 10.2217/lmt-2017-0001

Bibliografisk träff 2016-09-15

[Osimertinib (Tagrisso®): Activity, indication and modality of use in non-small cell lung cancer].

Giroux Leprieur E, Cortot AB, Cadranel J, Wislez M.

Bull Cancer · journal article · DOI 10.1016/j.bulcan.2016.06.007

Bibliografisk träff 2016-09-06

Osimertinib making a breakthrough in lung cancer targeted therapy.

Zhang H.

Onco Targets Ther · review-article; review; journal article · DOI 10.2147/ott.s114722

Bibliografisk träff 2016-04-01

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

Sequist LV, Piotrowska Z, Niederst MJ, Heist RS, Digumarthy S, Shaw AT, Engelman JA.

JAMA Oncol · letter; clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; research support, n.i.h., extramural · DOI 10.1001/jamaoncol.2015.5009

Bibliografisk träff 2016-03-01

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.

Pirker R.

Curr Opin Oncol · review; journal article · DOI 10.1097/cco.0000000000000260

Bibliografisk träff 2016-02-01

Osimertinib: First Global Approval.

Greig SL.

Drugs · review; journal article · DOI 10.1007/s40265-015-0533-4

Bibliografisk träff 2015-11-30

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.

Shea M, Costa DB, Rangachari D.

Ther Adv Respir Dis · research support, non-u.s. gov't; review-article; review; journal article; research support, n.i.h., extramural · DOI 10.1177/1753465815617871

Bibliografisk träff 2015-11-01

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.

Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, Naoki K, Costa DB, Kobayashi SS, Betsuyaku T, Soejima K.

Oncotarget · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.18632/oncotarget.5887

Gå till forskningen.

Publikationer i urvalet

A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.

Investigation of the mechanical effects of targeted drugs on cancerous cells based on atomic force microscopy.

New Adjuvant Drug for Lung Cancer.

Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease: A Systematic Review and Meta-analysis.

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

Osimertinib for the treatment of patients with <i>EGFR</i> mutation-positive non-small cell lung cancer.

Osimertinib - effective treatment of NSCLC with activating <i>EGFR</i> mutations after progression on EGFR tyrosine kinase inhibitors.

Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer.

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer.

AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with <i>EGFR</i> T790M mutation-positive locally advanced or metastatic NSCLC.

[Osimertinib (Tagrisso<sup>®</sup>): Activity, indication and modality of use in non-small cell lung cancer].

Osimertinib making a breakthrough in lung cancer targeted therapy.

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.

Osimertinib: First Global Approval.

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.